The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present at the 3rd Paris NASH Symposium, July 6 & 7, 2017

News detail

Return to all news & events

07/04/2017 Physiogenex to present at the 3rd Paris NASH Symposium, July 6 & 7, 2017

Physiogenex will be presenting several NASH animal models at the 3rd Paris NASH Symposium, July 6 & 7, 2017.

Dr. François Briand, Director of Research and Business Development at Physiogenex, will be presenting a poster during the poster sessions on July the 6th.

Check the 3rd Paris NASH Symposium website

If you wish to know more about running preclinical NASH experiments with us, ask Physiogenex experts

About Physiogenex

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.

Please visit our website for more information